Epidemiology and treatment utilization for Canadian patients with migraine: a literature review

Abstract

The objective of this narrative review was to identify real-world evidence regarding the burden of migraine in Canada. We conducted a literature search in MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for studies published between August 2010 and August 2020. Of the 3269 publications identified, 29 studies were included. Prevalence estimates varied widely across Canada, and mental health comorbidities were common. Individuals with migraine have a lower quality of life, detrimental impact on workforce productivity, and higher rates of health care resource utilization (HCRU), with HCRU and costs highest among those with chronic migraine. We found inconsistencies in care, including underutilization of medications such as triptans, and varied utilization of over-the-counter and prescription medications. Increased medication use was identified among those with chronic migraine, and only a small number of patients used migraine preventive medications. The burden of migraine in Canada is substantial. Reduced quality of life and workforce productivity, increased HCRU and costs, and underutilization of triptans and migraine preventive medications highlight an important need for more effective management of individuals with migraine.

Perles cliniques sur la prise en charge des migraines

“…es migraines sont courantes chez les patients au Canada, et leur prévalence s'élève à environ 10 % 1 . Par rapport aux hommes, les femmes sont de 2 à 3 fois plus susceptibles d'avoir des migraines 2 , et chez elles, la prévalence atteint son sommet en milieu de vie 3 .…”

Clinical pearls for management of migraines

“…igraines are common in patients in Canada, with a prevalence of around 10%. 1 Women are 2 to 3 times more likely than men to have migraines 2 and prevalence peaks in middle life. 3 Evidence suggests that migraines are undertreated in many patients; for example, less than 10% of Canadians with migraines use a triptan 4 and only around 30% of patients who might benefit from medications for migraine prophylaxis receive them.…”